The Vox Markets Podcast / Neil Clark & Shaun Claydon of Destiny Pharma: new funds will progress two lead clinical assets towards Phase 3 trials

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.